Neurofibroma - 181 Studies Found
Active, not recruiting |
: Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas :
|
Terminated |
: Phase I Clinical Study of the Safety of Photodynamic Therapy (PDT) Using LS11 in Children With Plexiform Neurofibromas : Neurofibroma : 2008-07-14 : Drug: LS11 LS11 will be given as a one-time IV infusion over 3-5 minutes. |
Terminated |
: First Clinical Study of Erbium - Yttrium Aluminium Garnet (YAG) Laser Vaporization of Cutaneous Neurofibromas : Cutaneous Neurofibromas : 2009-06-15 : Procedure: Erbium-YAG laser vaporization spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequen |
Completed |
: Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1 :
|
Active, not recruiting |
: Study of PEG-Intron for Plexiform Neurofibromas : Plexiform Neurofibroma : 2006-11-02 : Drug: PEG-Intron |
Completed |
: Ranibizumab for Neurofibromas Associated With Neurofibromatosis 1 :
|
Recruiting |
: Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas : Plexiform Neurofibromas : 2014-06-25 : Drug: Imatinib Mesylate oral administration Other Na |
Terminated |
: Efficacy and Safety of RAD001 in Treating Plexiform Neurofibromas (PN) Associated With Neurofibromatosis (NF1) : Plexiform Neurofibroma Associated With Neurofibromatosis Type 1 : 2011-05-27 : Drug: Everolimus (RAD001) oral daily dosing of tablet starting with 2.5 mg |
Completed |
: R115777 to Treat Children With Neurofibromatosis Type 1 and Progressive Plexiform Neurofibromas :
|
Active, not recruiting |
: Use of Topical Liquid Diclofenac Following Laser Microporation of Cutaneous Neurofibromas in Patients With NF1 :
|